Cipher Pharmaceuticals Inc. CPH

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") is pleased to announce the appointment of Rajiv De Silva to the Company's Board of Directors (the "Board"), effective today, September 21, 2026.

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") has received a favourable decision from the New York federal court (the "Court") regarding the petition filed by Sun Pharmaceutical Industries, Inc. ("Sun") in October 2025, seeking to partially vacate the portions of an arbitrator's award that affirmed Cipher's ownership of the clinical data involved in Sun's launch of Absorica LD® in Canada and granted remedies in Cipher's favour (the "Arbitration Award").

Despite a 10% revenue dip from Medicaid-related Natroba declines, Cipher boosts Epuris market share to 47.1% and secures a major Walmart retail partnership.

Cipher Pharmaceuticals (TSE:CPH) reported lower second-quarter revenue and earnings as sales of its U.S. Natroba treatment declined, while its Canadian Epuris product posted growth and market-share gains. Management said the company remains focused on expanding commercial channels for Natroba, widen

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced its financial and operating results for the three and six months ended June 30, 2026.

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance ("pCPA"), resulting in a Letter of Intent ("LOI") for Epuris® (isotretinoin).

Cipher Pharmaceuticals is back in focus as analysts refresh their models, with one key shift being a move in published price targets from CA$20 to CA$22 and a separate fair value estimate moving from CA$17.90 to CA$20.64. These higher targets are being framed as a reflection of stronger conviction rather than a call for a major change in the company’s current business plan. Read on to see what is driving the evolving analyst narrative and how you can track it over time. Analyst Price Targets...

Investors in Cipher Pharmaceuticals Inc. ( TSE:CPH ) had a good week, as its shares rose 9.8% to close at CA$19.74...

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or "the Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to commence a normal course issuer bid ("NCIB") for its common shares (the "Common Shares").

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the first quarter of 2026 after the market close on Thursday, May 7, 2026. The Company will also hold a conference call on Friday, May 8, 2026 at 8:30am ET to discuss the results and corporate developments.

The Canadian market, much like its global counterparts, is navigating a complex landscape where uncertainty around energy supply disruptions and geopolitical tensions looms large. Despite these challenges, the potential for small- and mid-cap stocks to sustain relative momentum offers intriguing opportunities for investors seeking growth. In this environment, identifying undiscovered gems requires a keen eye for companies with strong fundamentals that can thrive amidst cyclical shifts and...

Cipher Pharmaceuticals Inc (CPHRF) reports significant growth in revenue and net income, driven by Natroba sales and strategic debt reduction.